iBio Reports Fiscal Second Quarter 2022 Financial Results :

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

Related Keywords

United States , University Of Texas Southwestern Medical Center , Texas , American , Tom Isett , Stephen Kilmer , Fastpharming Contract Development , Texasam University , Drug Administration , Bio Inc , Eastern Capital Limited The Affiliates , Glycaneering Development Services , Company Annual Report On Form , While The Company , University Of Pittsburgh , Pharma Services , Manufacturing Services , Fastpharming Manufacturing , Recent Business Developments , Classical Swine Fever , Early Discovery , Late Discovery , Lead Optimization , Investigational New Drug , Texas Southwestern Medical Center , Eastern Capital Limited , Fastpharming Manufacturing Facility , Tracking Stock , Eastern Affiliates , Recent Corporate Developments , Reverse Stock Split , Authorized Shares , Glycaneering Development , Annual Report , Stockholder Equity , Consolidated Statements , Nyse Ibio , Bio , Nc ,